Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06533644 · ClinicalTrials.gov registry record · Phase 2

A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer

A Phase 2 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by Syncromune.

Recruiting
Registry status
Phase 2
Development phase
70
Enrollment target
9
Study locations

NCT06533644 is a Phase 2 study of Metastatic Castration-Resistant Prostate Cancer that is actively recruiting participants, run by Syncromune. The registered enrollment target is 70 participants, below the 197-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (64% lower). The trial reports 9 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06533644, a Phase 2 study of Metastatic Castration-Resistant Prostate Cancer, is actively recruiting participants, sponsored by Syncromune.

RECRUITING
Registry status
Phase 2
Development phase
70 participants
Enrollment target
9
Study locations

Study Summary

The primary purpose of this study is to evaluate the safety, tolerability, and efficacy of SYNC-T Therapy SV-102 and to identify the maximum tolerated dose (MTD) and/or selected dose for phase 2b study.

Conditions Studied

Metastatic Castration-Resistant Prostate Cancer

Interventions

  • PROCEDURE Partial Oncolysis
  • DRUG SV-102

Study Locations (9)

New York

  • Northwell Health - Lake Success
  • Weill Cornell - New York

Arizona

  • University of Arizona Cancer Center - Tucson

Illinois

  • Duly Health - Lisle

Kansas

  • Wichita Urology - Wichita

Michigan

  • Michigan Institute of Urology - Troy

Missouri

  • Mercy Hospital - St Louis

Nebraska

  • University of Nebraska Medical Center - Omaha

Pennsylvania

  • University of Pittsburgh Medical Center - Pittsburgh

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2025-05-29
Est. Completion 2027-12-14
Phase Phase 2

Sponsor

Syncromune

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06533644

The ClinicalTrials.gov registry entry for NCT06533644 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 197-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (64% lower). The listed sponsor is Syncromune, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Castration-Resistant Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Partial Oncolysis is the first listed.

NCT06533644 reports 9 study locations spanning 8 distinct geographic areas - top geographies include New York, Arizona, Illinois.

Frequently Asked Questions

What is clinical trial NCT06533644 about?

NCT06533644 is a clinical study titled "A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer". The primary purpose of this study is to evaluate the safety, tolerability, and efficacy of SYNC-T Therapy SV-102 and to identify the maximum tolerated dose (MTD) and/or selected dose for phase 2b study.

What is the current status of trial NCT06533644?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2025-05-29. Estimated completion is 2027-12-14.

What conditions does trial NCT06533644 study?

This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer.

What interventions are being tested in trial NCT06533644?

The interventions under investigation include: Partial Oncolysis (PROCEDURE), SV-102 (DRUG).

Who is sponsoring clinical trial NCT06533644?

This trial is sponsored by Syncromune, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06533644 being conducted?

This trial has 9 study locations across Arizona, Illinois, Kansas, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Castration-Resistant Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Castration-Resistant Prostate Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.